Year None20232022202120202019201820172016 Date Latest Press Release May 20, 2022 Eiger Receives Positive CHMP Opinion for Zokinvy as a Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies May 16, 2022 Eiger BioPharmaceuticals to Present at H.C. Wainwright Global Investment Conference May 10, 2022 Eiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zokinvy® (lonafarnib) in Japan May 5, 2022 Eiger BioPharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update April 29, 2022 Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) April 25, 2022 Eiger Announces Publication of Positive Phase 2 Results of Avexitide in Children with Congenital Hyperinsulinism and Initiation of Phase 3 Program April 21, 2022 Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2022 Financial Results and Business Update on Thursday, May 5 April 18, 2022 Eiger BioPharmaceuticals Strengthens Leadership Team with New Executive Appointments March 17, 2022 Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER Study March 16, 2022 Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 TOGETHER Study Results of Peginterferon Lambda for COVID-19 on Thursday, March 17, 2022 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
